Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Q3 2022 Earnings Presentation

42 slides from Marinus Pharmaceuticals's earnings presentation, Nov 7, 2022

  1. Slide 1: Third Quarter 2022 Corporate and Financial Update

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Third Quarter 2022 Corporate and Financial Update November 2022

  2. Slide 2: Forward-looking statements

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe

  3. Slide 3: Ganaxolone Development Pipeline

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 PDUFA date March 2022 MAA filing validation Q4 2021 Ph3 patient enrollment Q1 2022 Topline data 1H 2024 GANAXOLONE Phase 1 Phase 2 Phase 3 Approved Oral Suspension Intravenous Intravenous Intravenous Oral Suspensi

  4. Slide 4: Ganaxolone U.S. Market Opportunity

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 4 ¹ Symonds JD 2019 Brain ² Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657 – 68. ³DeLorenzo RJ et al. J Clin Neurophysiol .. 1995; 12: 316 - 325 4 Kapur et al. N Engl J Med 2019;381:2103 - 13 5 Rossetti and Lowenste

  5. Slide 5: ZTALMY (ganaxolone) oral suspension CV: Marigold Clinical Data & Commercial Launch

    ZTALMY ® (ganaxolone) oral suspension CV Marigold Clinical Data & Commercial Launch Not for promotional use

  6. Slide 6: Marigold Study: Seizure Frequency Reduction

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 6 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Difference Patients taking ganaxolone experienced a significant reduction in

  7. Slide 7: Progress Indicators Following July Commercial Launch

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Progress Indicators Following July 28 Commercial Launch 7 More than 50 prescription enrollment forms received for patients with CDD Over 30 new commercial patient enrollments Demand coming from over 40 unique accounts Positive coverage criteria fr

  8. Slide 8: ZTALMY U.S. Market Opportunity & Key Accounts

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY U.S. Market Opportunity & Key Accounts 8 ~2,000 Addressable Pediatric Patients * Several data points suggest additional market opportunity in adult population 1 Symonds JD 2019 Brain *Estimated based on Symonds JD 2019 Brain • 8 CDD Centers

  9. Slide 9: Rare Epilepsies Oral Ganaxolone Pipeline

    Rare Epilepsies Oral Ganaxolone Pipeline

  10. Slide 10: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  11. Slide 11: Tuberous Sclerosis Complex (TSC)

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 11 Tuberous Sclerosis Complex (TSC) 1 diMichele, et al, J. Neuro Neurosurg Psychiatry, 2003 *Failure of two prior antiseizure medications with ongoing, frequent seizures. CAUSE • Defect or mutation of TSC1 and/or TSC2 genes SYMPTOMS • Benign tumor

  12. Slide 12: TSC Phase 2 Trial Results

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 12 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC - associated

  13. Slide 13: Phase 3 Protocol Refinements Informed by Phase 2

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 13 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy 0 7 14 21 28 35 0 20 40 60 80 100 Time (days) Approx. % Max GNX Dose TSC Ph2 Titration TSC Ph3 Titration

  14. Slide 14: Phase 3 Trial Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 14 ► Enrollment: ~162 patients, targeting 85 sites in the U.S., Western Europe, Canada, Israel and Australia ► Primary Endpoint: Percent change in 28 - day TSC - associated seizure frequency ► Key Secondary Endpoints: Percen

  15. Slide 15: Second Generation Product Development

    Second Generation Product Development

  16. Slide 16: Second Generation Formulation Strategic Objectives

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Formulation 16 Strategic Objectives Enhanced Efficacy Achieve target blood levels to drive better clinical response Improved Safety Profile Optimize PK to mitigate somnolence levels Reduced Dosing Frequency More sustained serum l

  17. Slide 17: Second Generation Oral Ganaxolone Rationale and Phase 1 Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Oral Ganaxolone Rationale and Phase 1 Overview 17 Cohort 1 / 2 Treatment Six crossover treatment periods separated by 4 - day washout SCREENING Day - 1 thru – 28d Day 1 - Day 25 FOLLOW UP CALL Day 32 +/ - 2d Cohort 1 / 2 (n=6) Ph

  18. Slide 18: Ganaxolone Second-Generation Oral Formulation

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Second - Generation Oral Formulation 18 However, AUC increases linearly throughout the range of doses administered *Data on file. Studies 1042 - 0402 and 1042 - 0404, 7 - day multiple ascending dose studies with ganaxolone capsule formu

  19. Slide 19: Pathways to a Novel Oral Formulation for Lennox-Gastaut Syndrome

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Development plan goals • Efficiently select next generation product for clinical development in LGS and other potential indications • Proceed with targeted investments in parallel formulation and prodrug development to accelerate entry to Phase 2/

  20. Slide 20: Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

  21. Slide 21: Status Epilepticus

    Status Epilepticus

  22. Slide 22: Status Epilepticus (SE): Definition and Epidemiology

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology 22 SE is the second most common neurologic emergency in the U.S. 1 150,000 cases per year 2 1. Anesthesia and Intensive Care Medicine, February 02, 2018 , Update on the management of status epil

  23. Slide 23: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 23 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain 1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes 2 EEG bispectral index in healthy volunteers fol

  24. Slide 24: Strategic Approach to SE Clinical Development

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 24 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316 - 325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for St

  25. Slide 25: Refractory Status Epilepticus Trial (RSE) Design

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 25 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non - convulsive SE • Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics

  26. Slide 26: Phase 2 Trial Results Demonstrated Rapid Onset and Durability of Effect

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 26 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status - free throu

  27. Slide 27: PK/PD Relationship and Rationale for Target Dose

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I 27 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieved Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  28. Slide 28: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 28 Ganaxolone development for RSE is being funded, in part, by the Biomedical Advanced Research and Development Authority (BARDA ), part of the Office of the Assistant Secretary for Preparednes

  29. Slide 29: Patient Demographics: RSE Phase 2 vs. Phase 3

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Patient Demographics: RSE Phase 2 vs. Phase 3 29 * This is preliminary data is as of the end of Q3 2022 and may not be representative of demographics of patients upon full enrollment of the RAISE trial Ag e (mean range) Consented Subjects Dosed Hi

  30. Slide 30: RAISE Protocol Amended to Accelerate Enrollment

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE Protocol Amended to Accelerate Enrollment 30 Original Protocol Amended Protocol Patients excluded IF SE would NOT warrant anesthesia for the next 24 hours IV anesthesia would likely be next treatment if study drug (ganaxolone or placebo) doe

  31. Slide 31: RESET: Phase 2 Trial in Established Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RESET: Phase 2 Trial in Established Status Epilepticus 31 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103 - 13. Key Trial points: • Patients with convulsive status epilepticus •

  32. Slide 32: RESET Trial Design in Established Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RESET Trial Design in Established Status Epilepticus 32 Screening <30 min Enrollment Fail BZD IV ganaxolone infusion 1 IV ganaxolone infusion 3 SOC IV AED Convulsive SE (N=40) Ganaxolone bolus Ganaxolone bolus Ganaxolone bolus Seizures YES NO Seiz

  33. Slide 33: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 33 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103 - 13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV An

  34. Slide 34: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  35. Slide 35: Clinical and Healthcare Costs Associated with RSE

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 35 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  36. Slide 36: Differentiated Market Access Strategy for IV Ganaxolone

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Differentiated Market Access Strategy to Ensure Success for IV Ganaxolone Formulation 36 (DRG), diagnosis - related group reimbursement PRICING & REIMBURSEMENT • U.S./EU Pricing research initiated and ongoing • Determining New Technology Add - on

  37. Slide 37: Financial Update

    Financial Update

  38. Slide 38: Financial Overview: Q3 2022

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview: Q3 2022 38 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann : Michael

  39. Slide 39: Liquidity Overview

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Liquidity Overview 39 Note: All values shown ar e gross transactional proceeds 1 Marinus potential to draw subject to achievement of certain clinical and financial milestones Financial Summary (as of September 30 , 2022) : • $168.2 million in cash

  40. Slide 40: U.S. Revenue Interest Financing

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I U.S. Revenue Interest Financing 40 U. S. revenue interest financing agreement with Sagard Healthcare Partners ( Sagard ) , a multi - strategy alternative asset manager, including healthcare royalties, with more than US$14 billion under management

  41. Slide 41: Intellectual Property

    Intellectual Property

  42. Slide 42: Multiple Layers of Potential Protection

    ©2022 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 42 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. Paten

Marinus Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix